Piflufolastat F-18 medicamentos de inyección (Pylarify) de Lantheus (Nota de Intent a su única fuente)

Ficha

Fechas

Publicada22 sep 2026Cierre de ofertas29 sep 2026 · 14:00 (hora de UTC)

Descripción oficial

Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Progenics Pharmaceuticals Inc. The National Institute of Health, Clinical Center (NIH-CC)’s has the Nuclear Pharmacy (CC NP) department (collectively “Program”) that purchases and compounds radiopharmaceuticals (radioactive drugs) on a daily basis for life-saving clinical nuclear medicine procedures. This is essential for the NIH Clinical Center to achieve optimal patient care. These radiopharmaceuticals are United States Food and Drug Administration (FDA) approved drugs for use in patients. They are also radioactive materials that are regulated by the United States Nuclear Regulatory Commission (US NRC) through the NIH radioactive material license (RAM) administered by the NIH Radiation Safety Office (RSO). Only RSO certified Nuclear Medicine personnel can order these radiopharmaceuticals directly for patient use. Each radiopharmaceutical is time sensitive because of the rapid radiation decay. Because of their short useful half-lives, they cannot be ordered in advance for storage. They must be properly compounded, dispensed, calibrated and delivered for a specific patient at a specific time on a specific date on a daily basis. The purpose is to procure compounded piflufolasta F-18 in patient ready unit doses (UDs) from an authorized nuclear pharmacy for the use by the NIH Nuclear Medicine, Department of Radiology and Imaging Sciences to diagnose and treat diseases as required by necessary patient care protocols at the NIH Clinical Center. This new radioactive drug is vital to the NIH Clinical Center mission. The product is owned and developed by Lantheus Medical/Progenics Pharmaceuticals (now merged as one company). Progenics Pharmaceuticals Inc uses Lantheus’ Federal Supply Schedule contract on contract 36F79719D0170. Justification and other information: This requirement will be sole sourced to Progenics Pharmaceuticals Inc. under FAR 8.405-6 (b): Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized. This notice is being made on SAM.gov instead of GSA Ebuy because the GSA Ebuy category “65 I B PHARMACEUTICALS AND DRUGS” states that “This SIN is not available through GSA Advantage.” Lantheus Medical Imaging (a company of Lanntheus Holding, Inc.) is the developer and intellectual property owner of Piflufolastat F-18 injection drugs (Pylarify) in the United States. More specifically, Progenics Pharmceuticals had been developing this drug and Lantheus merged Progenics Pharmaceuticals. Progenics Pharmaceuticals Inc is the only local authorized commercial nuclear pharmacy authorized by Lanthesus Medical Imaging to compound, prepare, delivery and invoice for these drugs. They use the Federal Supply Schedule contract on con

Cómo participar

1. Registra tu empresa en SAM.gov (es gratis) para obtener el identificador único de entidad (UEI). La mayoría de las solicitudes exigen el registro activo al presentar la oferta, y el trámite puede tardar varias semanas.
2. Abre el aviso en SAM.gov y lee la solicitud, sus anexos y cada enmienda.
3. Presenta tu oferta exactamente como indica el aviso, antes de la fecha de respuesta.